Many lines of evidence implicate mitochondria in phenotypic variation: (a) rare mutations in mitochondrial proteins cause metabolic, neurological, and muscular disorders; (b) alterations in oxidative phosphorylation are characteristic of type 2 diabetes, Parkinson disease, Huntington disease, and other diseases; and (c) common missense variants in the mitochondrial genome (mtDNA) have been implicated as having been subject to natural selection for adaptation to cold climates and contributing to "energy deficiency" diseases today. To test the hypothesis that common mtDNA variation influences human physiology and disease, we identified all 144 variants with frequency 11% in Europeans from 1900 publicly available European mtDNA sequences and selected 64 tagging single-nucleotide polymorphisms that efficiently capture all common variation (except the hypervariable D-loop). Next, we evaluated the complete set of common mtDNA variants for association with type 2 diabetes in a sample of 3,304 diabetics and 3,304 matched nondiabetic individuals. Association of mtDNA variants with other metabolic traits (body mass index, measures of insulin secretion and action, blood pressure, and cholesterol) was also tested in subsets of this sample. We did not find a significant association of common mtDNA variants with these metabolic phenotypes. Moreover, we failed to identify any physiological effect of alleles that were previously proposed to have been adaptive for energy metabolism in human evolution. More generally, this comprehensive association-testing framework can readily be applied to other diseases for which mitochondrial dysfunction has been implicated. 
Mitochondria play a central role in energy metabolism, are composed of 1700 known proteins, 1 and are essential for generating ATP and for regulating apoptosis. 2 The human mitochondrial oxidative phosphorylation (OXPHOS) machinery, which synthesizes most intracellular ATP, consists of five complexes with 85 known protein subunits. Thirteen OXPHOS subunits, 2 rRNA genes, and 22 tRNA genes are encoded by the 16.6-kb mitochondrial genome (mtDNA).
Rare mutations in both nuclear-encoded OXPHOS genes and in mtDNA result in disease syndromes with neurological, muscular, or metabolic manifestations, proving that defects in mitochondrial OXPHOS can play a causal role in human disease. Mutations in nuclear-encoded components of OXPHOS complexes have been identified in many early-onset diseases, such as Leigh syndrome (MIM 256000) and cardioencephalomyopathy (MIM 604377). 2, 3 Nuclear genes that encode OXPHOS assembly factors, influence mtDNA maintenance or translation, modify mitochondrial tRNA, or encode biosynthetic enzymes may be mutated in rare mitochondrial diseases. 4, 5 In addition, 1250 mtDNA point mutations and deletions have been linked to human disease, and several of these include glucose defects or diabetes mellitus as component phenotypes-for example, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS [MIM 540000]), Kearns-Sayre syndrome (KSS [MIM 530000]), and maternally inherited diabetes and deafness syndrome (MIDD [MIM 520000]). 6, 7 A mutation in the mitochondrial Leu tRNA gene (A3243G) causes MIDD, 8 and a novel substitution in a highly conserved region of the mitochondrial Ile tRNA gene (T4291C) causes hypertension, hypercholesterolemia, and hypomagnesemia (MIM 500005), 9 suggesting that mutations in mtDNA can cause diabetes and other metabolic defects.
Alterations in the function of OXPHOS have been recognized consistently in type 2 diabetes (MIM 125853). Reduced activity of OXPHOS enzymes and fewer, smaller mitochondria are seen by transmission electron microscopy in skeletal muscle from diabetics compared with nondiabetics. [10] [11] [12] From global gene-expression-profiling studies, we and others identified a subset of OXPHOS genes that are co-coordinately downregulated in muscles from individuals with type 2 diabetes compared with healthy control individuals. 13, 14 In addition, functional in vivo spectroscopy studies demonstrate that OXPHOS ac- tivity and rates of ATP synthesis are lower in the insulinresistant offspring of diabetic individuals and in elderly insulin-resistant people. [15] [16] [17] Population genetics analysis has suggested a functional role for common variants in mtDNA. On the basis of differential conservation of missense variants in different mtDNA lineages, it was argued that positive selection influenced common mtDNA variation. Moreover, it was hypothesized that mtDNA SNPs favorable for selective adaptation to cold Northern climates during human evolution predispose to energy metabolism diseases today. 2, 18, 19 These many lines of evidence suggest a "mitochondrial" hypothesis of disease. Specifically, inherited defects in mitochondria may play a causal role in type 2 diabetes 20, 21 and neurodegenerative diseases, such as Alzheimer (MIM 104300), Parkinson (MIM 168600), and Huntington (MIM 143100) diseases. 22, 23 Population genetics analysis specifically suggests that common mtDNA variants may be functional and relevant to disease. However, no comprehensive test, even of common variation in mtDNA, has yet been performed. Several previous reports did not consistently reproduce associations of common mtDNA variants with diabetes or metabolic traits. [24] [25] [26] [27] [28] [29] However, these studies tested only a subset of mtDNA variation in relatively modestly sized samples of !2,000 individuals.
The goal of the present study was to perform a comprehensive test of the hypothesis that mtDNA variants influence type 2 diabetes and metabolic traits. Specifically, we sought to (1) inventory all SNPs with frequency 11% in Europeans, (2) select tagging SNPs (tSNPs) to capture this variation efficiently, (3) test all common variants and haplogroups for association with type 2 diabetes and a range of metabolic phenotypes (although sample sizes for some traits were limited), and (4) assess studywide significance of our findings by permutation testing.
Material and Methods

Alignment of Sequences
We aligned all human mtDNA coding-region sequences from GenBank (719 sequences) and 536 sequences from Mitokor 30 and identified 3,240 variant sites. We excluded ∼0.8 kb of the hypervariable mtDNA D-loop promoter region from the study, since this region is best addressed by direct resequencing in case-control samples because of its high mutation rate.
Subjects and Samples
The sample consisted of 6,608 white subjects from Scandinavia (Sweden and Botnia, hereafter referred to as the "Swedish" and 4 , tSNPs were genotyped in a diabetic case-control panel with available metabolic phenotypes. 5, All hypotheses to be tested were enumerated. 6, Association tests were performed. 7, Studywide significance of results was assessed by permutation (multiple rounds of association testing with randomization of casecontrol labels or, for quantitative measures, shuffling within a population).
"Scandinavian" samples, respectively), Canada, Poland, and the United States; metabolic phenotype information was available for a subset of the subjects (table 1) . 31, 32 The Scandinavian and Canadian diabetic case-control samples were matched for sex, age, region, and BMI (calculated as weight in kilograms divided by the square of height in meters), whereas the Polish and U.S. casecontrol samples were matched for sex, age, and geographical region but not tightly for BMI. BMI, blood pressure, and cholesterol values were available for diabetic and nondiabetic subjects from all five populations, and insulinogenic index and homeostasis model assessment of insulin resistance (HOMA-IR) values were obtained for nondiabetic Scandinavian and Swedish subjects (from a 2-h oral glucose tolerance test [OGTT] ). The study of human subjects was approved by the institutional review boards at parent institutions for all samples and at the Broad Institute for Harvard and MIT. Genomic DNA was extracted from blood samples and lymphoblastoid cell lines.
Genotyping
Genotyping was performed by primer extension of multiplex products with detection by matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy with use of a Sequenom platform. 33 Genotyping for the 64 tSNPs was 198%; maternal inheritance was confirmed for tSNPs by genotyping in 117 CEPH trios (not shown). Two SNPs (mt14470 and mt15884) were triallelic in this population. Duplicate genotypes were obtained for ∼20% of the sample with 22 SNPs and were highly concordant (0.1% discordant genotypes of 29,462 duplicate comparisons). For 69 samples (1.1% of samples genotyped), we observed spectral peaks for both the major and minor allele for 1-3 SNPs per sample. In total, 21 SNPs had heterozygous calls in at least one individual. These observations are consistent with either DNA contamination or heteroplasmy (more than one mtDNA haplotype arising from somatic/maternal germ line mutations or from the paternal mtDNA contribution). Signals for both alleles were seen in individuals from all populations, and no significant difference in the number of cases and controls with such genotypes was observed. For analysis, these genotypes were treated as missing data.
Results
Previous studies have tested subsets of mtDNA variants (from 10-32 sites) for association with a variety of traits, [24] [25] [26] [27] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] typically focusing on the nine canonical haplogroups. 50 We began by cataloging all common sites (frequency 11%) in 15,770 bp of mtDNA (excluding the coding region) and by evaluating how well the complete inventory is captured by these canonical haplogroups in mtDNAs of European origin. Alignment of 928 European coding-region mtDNA sequences (115,770 bp) identified 2,349 variable sites; 144 sites had a frequency 11% in European individuals (1 site per 110 bp), including 37 nonsynonymous variants, 81 synonymous variants, 25 rRNA/ tRNA variants, and 1 noncoding variant (table 2) . Fifty variants with frequency 15% were identified. The common variants (frequency 11%) explained 72% of the "heterozygosity" in the European population; this is notably less than in the nuclear genome, where ∼90% of heterozygosity is due to common variants. [51] [52] [53] Evaluation of previous sets of tSNPs used for disease association studies revealed that ∼30% of variants (frequency у1%) are captured with (table 3) . Re-2 r у 0.8 cently, 27 more-complete coverage of mtDNA variation was reported using 32 mtDNA SNPs; still, these SNPs capture less than half of the sites (42%) at . Thus, previous 2 r у 0.8 studies might have missed a true association simply because not all variants were captured by the tSNPs used.
We selected a set of 64 SNPs that capture each of the 144 sites as well as the nine haplogroups with , 2 r у 0.8 using Tagger 54 ; tSNPs and predictive tests are listed in table 4. Details on the assay conditions are available online (Broad Institute Tagger: SNPs in human mtDNA Web site).
As a framework to test common mtDNA variants for association with clinical traits ( fig. 1) , we first enumerated all hypotheses to be tested for association. Specifically, we sought to test for association with each phenotype for each of the individual 144 variant sites with frequency 11% as well as for the nine previously codified European haplogroups. Association tests for type 2 diabetes (the dichotomous trait) were performed by x 2 comparisons, 2 # 2 and, for quantitative phenotypes, by linear regression. Studywide significance (P study ) was empirically evaluated by permutation testing (association studies were repeated 50-1,000 times by using randomized phenotype labels within each case-control pair for diabetes and by using randomized trait values within each of five populations for quantitative traits). We also tested all pairwise combinations of single variants with a nominal P value (P nom ) !.1 (another ∼600 correlated hypotheses) for association with diabetes and BMI. 55 As a test of the hypothesis that common mtDNA variation plays a causal role in disease, we considered association with type 2 diabetes and metabolic traits. We genotyped each of the 64 tSNPs in a diabetes case-control sample of 6,608 subjects, with quantitative measurements available for a subset of subjects (table 1) . Under the assumption of ∼100 independent tests performed in this study, this sample has 177% power to reject the null hypothesis of no association between mtDNA variants and type 2 diabetes at for a 5% risk allele with a 1.5 P ! .05 genotype relative risk and has 198% power for risk alleles with frequency 110%. 56 Allele frequencies for SNPs differed across the populations tested (table 5) .
Results from association studies with type 2 diabetes and BMI are shown in tables 6, 7, and 8. For diabetes, only two hypotheses with were found, and these re-P ! .05 nom sults were far from significant after permutation testing (50-1,000 iterations for each association test) (P p study ). For BMI, we found no significant association before .55 ( ) or after ( ) adjustment for sex and P p 1.0 P p .25 study study age. Tests for epistasis did not demonstrate any significant association with diabetes or BMI. Subanalysis of association with diabetes by population failed to show any strong effects in U.S., Scandinavian, and Canadian populations (tables 9 and 10). A significant association result was observed in the Polish subpopulation after permutation testing ( after 1,000 permutations); however, P p .02
Polish study
given that mtDNA variants from five populations were tested for association with diabetes, this result is consistent with noise and thus would need to be validated by replication in other large Polish samples. The remaining quantitative metabolic traits were studied only in nondiabetic controls, and sample sizes for these additional studies were significantly smaller than for diabetes or BMI (tables 6, 7, and 8). No significant associations were identified using unadjusted models for insulin resistance (HOMA-IR), insulin secretion (insulinogenic index), cholesterol levels, and systolic and diastolic blood pressure (table 6) or after adjustment for sex, age, and BMI (tables 7 and 8).
We specifically examined the results for the three missense variants that were hypothesized to have been adaptive in cold climates and to be related to "energy deficiency" diseases today. 18, 19 No association with increased risk of diabetes, obesity, or other metabolic traits was observed ( 
Discussion
We set out to develop a comprehensive approach to mtDNA association testing that (a) captures all common coding-region mtDNA variants and haplogroups efficiently by use of linkage disequilibrium, (b) tests all common variants for association, and (c) accounts for the multiple comparisons implicit in testing the many variants in mtDNA. Compared with the methods in the literature, this approach provides a more complete and statistically conservative assessment of the role of common mtDNA variants in disease; the current application to diabetes and BMI provides a sample size threefold larger than any previous study. Despite this well-powered evaluation, our analyses do not support the hypothesis that common mtDNA variants play a role in type 2 diabetes and BMI, at least in the European samples studied. The results from our association tests of all common mtDNA variants and the risk of type 2 diabetes show that there is no single common coding-region mtDNA variant in European populations that strongly influences risk of type 2 diabetes or BMI, which is consistent with recent results obtained by Mohlke et al. 27 Haplogroup association results for type 2 diabetes were also consistent with noise. There may be populationspecific variants that confer altered risk of diabetes (as in the Polish sample tested here), and further studies, including replication and complete resequencing, 57 will be needed to explore that hypothesis. Our results showed no significant association of mtDNA variants with other metabolic traits (blood pressure, cholesterol, insulin secretion, and insulin resistance traits); however, this study was not as well powered for these traits. It is interesting and perhaps surprising that we could not detect any phenotypic consequence of missense variants that were predicted to have been selected for in colder climates. 2, 19, 58 Although our study does not directly address the hypothesis that climatic influences have led to selective adaptation of mtDNA variants, if common mtDNA variation does influence such traits, it is not reflected in glucose-stimulated insulin secretion, insulin resistance, body weight, blood pressure, cholesterol level, or type 2 diabetes.
This study does not address the role of mtDNA heteroplasmy in diabetes. Acquired somatic mtDNA mutations in tissues of relevance to type 2 diabetes are undetected in the blood samples used here. Typically, blood DNA exhibits much less heteroplasmy than nondividing tissues. 59 In the 6,608 DNA samples tested, a very small amount of heteroplasmy was observed (1.1% of samples had one or more "heterozygous" calls), although the mass spectroscopy-based genotyping platform is sensitive to low-frequency spectral peaks corresponding to the alternate allele. Rare mitochondrial diseases exhibit more pronounced heteroplasmy, perhaps because cells with mutant alleles are inviable without wild-type mtDNA molecules. Thus, we think it is unlikely that mtDNA heteroplasmy for inherited variants significantly influenced our results.
These results should not be taken as addressing the broader hypothesis that mitochondrial OXPHOS plays a causal role in type 2 diabetes; there are 170 nuclear-encoded OXPHOS subunits and an estimated 1,500 mitochondrial proteins that are as yet untested. Moreover, although the mtDNA variants tested here do not appear to influence metabolic disease, inherited variation in mtDNA may influence risk of other diseases, such as Alzheimer disease, Parkinson disease, cardiovascular disease, cardiomyopathy, HIV lipodystrophy, and prostate cancer. A systematic evaluation of mtDNA and nuclear mitochondrial genes for a causal role in these diseases and an investigation of epistatic interactions between the two genomes will reveal the extent to which mitochondrial defects play a causal role in human disease.
